All In Biotech

Drug Trial Radar · NCT04202653

Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)

New Combination of ETV, TQ-A3334 and TQ-B2450 for the Treatment of Chronic Hepatitis B Virus Infection

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jan 1, 2020

Primary completion

Jun 30, 2023

Study completion Dec 31, 2023

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
First posted
Dec 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B patients. Patients were randomized to one of 3 different antiviral treatment.

Conditions

  • Chronic Hepatitis b

Interventions

  • ETVDrug

    entecavir 0.5 mg qd

  • TQ-A3334Drug

    TQ-A3334 po qw

  • TQ-B2450Drug

    TQ-B2450 q3w iv

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in HBsAg quantification at week 24Time frame: week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.